narcolepsy type 1
Selected indexed studies
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. (N Engl J Med, 2025) [PMID:40367374]
- The immunopathogenesis of narcolepsy type 1. (Nat Rev Immunol, 2024) [PMID:37400646]
- Narcolepsy type 1: what have we learned from genetics? (Sleep, 2020) [PMID:32442260]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. (2025) pubmed
- Narcolepsy type 1: what have we learned from genetics? (2020) pubmed
- Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1. (2023) pubmed
- The immunopathogenesis of narcolepsy type 1. (2024) pubmed
- Narcolepsy type 1: what have we learned from immunology? (2020) pubmed
- [Narcolepsy type 1 and hypocretin neurons]. (2025) pubmed
- Recent insights into the pathophysiology of narcolepsy type 1. (2024) pubmed
- Unraveling the pathophysiology of narcolepsy type 1 through hypothesis-driven and hypothesis-generating approaches. (2025) pubmed
- The Role of T Cells in the Pathogenesis of Narcolepsy Type 1: A Narrative Review. (2024) pubmed
- Infection, vaccination and narcolepsy type 1: Evidence and potential molecular mechanisms. (2024) pubmed